Cases in this study were population-based unlike several previous TMPRSS2-ERG studies [4,5,18,19], there was a mean surveillance period of 11.6 years after diagnosis, and prostate cancer-specific death was confirmed by death certificate. The gene discussed is TMPRSS2; the disease is prostate carcinoma.